Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - tixagevimab 100 mg/ml;  ; cilgavimab 100 mg/ml;   - solution for injection - 100 mg/ml - active: tixagevimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection active: cilgavimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection - evusheld is indicated for the pre-exposure prophylaxis of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg, - who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to covid-19 vaccination or - for whom vaccination with any approved covid-19 vaccine is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a covid-19 vaccine(s) and/or covid-19 vaccine component(s).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - benralizumab 30 mg/ml - solution for injection - 30 mg/ml - active: benralizumab 30 mg/ml excipient: histidine histidine hydrochloride polysorbate 20 trehalose water for injection - fasenra is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count nlt 300 cells/µl or nlt 150 cells/µl if on oral corticosteroid treatment).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug;  ;  ;  ; formoterol fumarate 4.5ug;   - aerosol inhaler, metered dose - active: budesonide 80ug       formoterol fumarate 4.5ug   excipient: apaflurane macrogol 1000 povidone - vannair 100/6 and 200/6 are indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta-2-agonist) is appropriate. this includes: - patients who are not adequately controlled with inhaled corticosteroid therapy and "as needed" inhaled short-acting beta-2 adrenoceptor agonists. - patients who are already adequately controlled on regular separate long acting beta-agonist and inhaled corticosteroid therapies.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 160ug;  ;  ;  ; formoterol fumarate 4.5ug;   - aerosol inhaler, metered dose - active: budesonide 160ug       formoterol fumarate 4.5ug   excipient: apaflurane macrogol 1000 povidone - vannair 100/6 and 200/6 are indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta-2-agonist) is appropriate. this includes: - patients who are not adequately controlled with inhaled corticosteroid therapy and "as needed" inhaled short-acting beta-2 adrenoceptor agonists. - patients who are already adequately controlled on regular separate long acting beta-agonist and inhaled corticosteroid therapies.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - acalabrutinib 100mg - capsule - 100 mg - active: acalabrutinib 100mg excipient: black ink (calquence) gelatin indigo carmine iron oxide yellow magnesium stearate silicified microcrystalline cellulose sodium starch glycolate starch titanium dioxide - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll).

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - azd-1222 (unii: b5s3k2v0g8) (azd-1222 - unii:b5s3k2v0g8) -

Uniunea Europeană - engleză - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Africa de Sud - engleză - South African Health Products Regulatory Authority (SAHPRA)

astrazeneca pharmaceuticals (pty) ltd - injection - see ingredients - each 5,0 ml solution contains fulvestrant 250,0 mg

Africa de Sud - engleză - South African Health Products Regulatory Authority (SAHPRA)

astrazeneca pharmaceuticals (pty) ltd - capsules - see ingredients - each capsule contains acalabrutinib 100,0 mg

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

astrazeneca limited - sodium chloride 0.9% - solution for injection - 0.9% w/v - active: sodium chloride 0.9% excipient: hydrochloric acid water for injection